Karyopharm Therapeutics Inc. Common Stock (KPTI)

FairStock Score: 18/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style search for durable earnings and a margin of safety. Karyopharm is a commercial-stage biotech with fiscal year 2025 revenue, the year ended 2025-12-31, of $146.1M, roughly flat from fiscal year 2024 revenue of $145.2M and fiscal year 2023 revenue of $146.0M. But revenue stability has not produced profits. Net losses were -$143.1M in fiscal year 2023, -$76.4M in fiscal year 2024, and -$196.0M in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $33.4M and net income was -$67.0M, a -200.48% margin. Diluted EPS was -$2.32 in that quarter, and the latest figures show continuing red ink. The balance-sheet and cash-flow picture is alarming. FairStock's trailing free cash flow is -$65.3M, a -674.7% FCF yield against the $9.7M market cap at the 2026-10-13 close. FairStock's Piotroski score is 3/9 and Altman Z-score is -23.91, both pointing to distress rather than strength. At that close of $0.43, FairStock's P/E calculation is -0.03 and the FairStock Score is 18/100. The company has no dividend and negative ROCE of -47.61%. FairStock assigns no Peter Lynch category, because the company lost money in each of the last four years. A value investor asks what protects the downside. Here, there is no earnings record, no shareholder yield, and no visible margin of safety from the provided figures. The stock trades near its 52-week low of $0.40, far below the $10.99 high, and the market is pricing in severe doubt. If losses narrowed sharply while revenue held near $146.1M, the tiny market cap could look cheap. But the current evidence is of a loss-making, cash-consuming biotech, not a Graham bargain.

In plain English: Karyopharm Therapeutics is a commercial-stage cancer drug company with a medicine called XPOVIO. The business is weak: it has lost money every year, including a large loss in the latest quarter, and it is burning cash. At $0.43 per share on 2026-10-13, the price looks less like a bargain and more like a distressed bet, because the losses are very large compared with the company's tiny $9.7M market value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer